



PTO/SB/08 Equivalent

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Multiple sheets used when necessary) SHEET 1 OF 1	Application No.	10/777053
	Filing Date	February 10, 2004
	First Named Inventor	John J.L. Simard
	Art Unit	1644
	Examiner	Francois P. Vandervegt
	Attorney Docket No.	MANNK.022C1

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1				
	2				
	3				
	4				
	5				
	6				
	7				
	8				

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
PV	9	WO 01/82963 A	11/08/2001	Simard et al.		
	10					
	11					
	12					
	13					

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	14		
	15		
	16		
	17		
	18		

2347614 / 020206

Examiner Signature	/F. Pierre Vandervegt/	Date Considered	05/31/2006
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

T¹ - Place a check mark in this area when an English language Translation is attached.



PTO/SB/08 Equivalent

SUPPLEMENTAL INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(Multiple sheets used when necessary)

SHEET 1 OF 2

Application No.	10/777,053
Filing Date	February 10, 2004
First Named Inventor	John Simard
Art Unit	1644
Examiner	Vandervegt, Francois P.
Attorney Docket No.	MANNK.022C1

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
PV	1.	2003/0220239	11-2003	Simard, et al.	
PV	2.	2005/0130920	06-2005	Simard, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
PV	3.	WO 99/45954	09-1999	Sette, et al.		
PV	4.	WO 01/55393	08-2001	Wang, et al.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
PV	5.	Bergmann, et al. "Differential Effects of Flanking Residues on Presentation of Epitopes from Chimeric Peptides." J. Virol. 5306-5310 (1994).	
PV	6.	Celis, et al. "Identification of Potential CTL Epitopes of Tumor-Associated Antigen Mage-1 for Five Common HLA-A Alleles." Mol. Immunol. 31(18): 1423-1430 (1994).	
PV	7.	Chaux, et al. "Estimation of the Frequencies of Anti-Mage-3 Cytolytic T-Lymphocyte Precursors in blood from Individuals without Cancer." Int. J. Cancer. 77:538-542 (1998).	
PV	8.	Eisenlohr, et al. "Flanking Sequences Influence the Presentation of an Endogenously Synthesized Peptide to Cytotoxic T Lymphocytes." J. Exp. Med. 175: 481-487 (1992).	
PV	9.	Gileadi, et al. "Effect of Epitope Flanking Residues on the Presentation of N-Terminal Cytotoxic T Lymphocyte Epitopes." Eur. J. Immunol. 29: 2213-2222 (1999).	
PV	10.	Gnjatic, et al. "Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses." PNAS USA. 100(15): 8862-8867 (2003).	
PV	11.	Gnjatic, et al. "Cross-Presentation of HLA Class I Epitopes from Exogenous NY-ESO-1 Polypeptides by Nonprofessional APCs." J. Immunol. 170: 1191-1196 (2003).	
PV	12.	Ochoa-Garay, et al. "The Ability of Peptides to Induce Cytotoxic T Cells <i>In Vitro</i> Does Not Strongly Correlate with their Affinity for the H-2Id Molecule: Implications for Vaccine Design and Immunotherapy." Molecular Immunology. 34(3): 273-281 (1997).	
PV	13.	Perkins, et al. "Immunodominance: Intramolecular Competition Between T Cell Epitopes." J. Immunol. 146: 2137-2144 (1991).	
PV	14.	Shastri, et al. "Presentation of Endogenous Peptide/MHC Class I Complexes is Profoundly Influenced by Specific C-Terminal Flanking Residues." J. Immunol. 155: 4339-4346 (1995).	

Examiner Signature /F. Pierre Vandervegt/	Date Considered 05/31/2006
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Multiple sheets used when necessary)</i>	Application No.	10/777,053
	Filing Date	February 10, 2004
	First Named Inventor	John Simard
	Art Unit	1644
SHEET 2 OF 2		Attorney Docket No. MANNK.022C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
PV	15.	Wang, et al., "New NY-ESO Cancer Peptide or MHC Class II Restricted T Cell Epitopes, Useful as Immunogen and Vaccine for Inhibiting Cancer in a Mammal or as Protection From Metastasis." N Geneseq Accession No. AAD14184, 06 November 2001, page 2.	
PV	16.	Theobald, et al. "The Sequence Alteration Associated with a Mutational Hotspot in P53 Protects Cells from Lysis by Cytotoxic T Lymphocytes Specific for a Flanking Peptide Epitope." J. Exp. Med. 188(6): 1017-1028 (1998).	
PV	17.	Wang, et al. "Silencing of Immunodominant Epitopes by Contiguous Sequences in Complex Synthetic Peptides." Cell. Immunol. 143: 284-297 (1992).	

2424141 SMA030706

Examiner Signature	/F. Pierre Vandervegt/	Date Considered	05/31/2006
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			

T¹ - Place a check mark in this area when an English language Translation is attached.